Skip to main content
Premium Trial:

Request an Annual Quote

Roche Licenses NuGen Technology for RNA Amplification Kit

NEW YORK (GenomeWeb News) – Roche announced today that it has licensed technology from NuGen Technologies that will be included in Roche’s LightCycler RNA Pre-Amplification Kit, which will be launched in the third quarter of 2008.
 
Under the co-exclusive agreement, NuGen will supply components for the kit and has provided Roche with limited access to NuGen’s Ovation technology, which enables small and partially degraded RNA samples to be amplified into micrograms of cDNA.
 
The new LightCycler Kit will allow researchers to conduct whole-transcriptome gene expression analysis of challenging clinical samples, Roche said in a statement. The firm believes NuGen’s whole-transcriptome RNA amplification methodology will provide it with an advantage over competitors by enabling high-throughput, multi-test real-time PCR assays that have a quicker time to result.
 
Elizabeth Hutt, CEO of San Carlos, Calif.-based NuGen said that Roche’s use of the Ovation technology “is an important validation of the precision of our RNA amplification technology.”
 
Financial terms of the deal were not disclosed.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.